Sinusoidal and Canalicular Transporter Topology

Why Membrane Topology Matters

A hepatic transporter’s location helps define which compartments a molecule can reach. Uptake from blood across the sinusoidal membrane moves a compound into a hepatocyte. Efflux across that same membrane returns material to blood, whereas efflux across the canalicular membrane sends it toward bile. These routes can produce different systemic exposure and elimination patterns, even when the molecule enters the same cell.

Topology is a map of possible crossing routes, not a complete account of transport rate or net disposition. The route taken depends on transporter abundance and activity, substrate properties, gradients, energy coupling, and competing processes. Those kinetic and quantitative details require additional evidence. Here the objective is narrower: identify the membrane, the side a transporter faces, and the direction of the crossing being considered.

A useful first-pass map is therefore: blood → sinusoidal membrane → hepatocyte, followed by one or more possible fates. Material may leave through the sinusoidal membrane and return to blood, cross the canalicular membrane into bile, remain within the cell, or undergo metabolism. A transporter name should be assigned to a crossing only when its membrane location and transport direction are relevant to that crossing.

A Topology Map of Hepatic Transporters

Several uptake transporters are typically located on the sinusoidal membrane. Organic anion transporting polypeptides OATP1B1 and OATP1B3 are important examples for hepatic uptake of various organic anions and drugs. The sodium taurocholate cotransporting polypeptide NTCP is a major route for uptake of bile acids and related substrates. Organic cation transporter OCT1 is another sinusoidal uptake transporter for selected organic cations. These examples do not imply that every member transports every substrate, or that the transporter is the only route by which a substrate enters.

Efflux occurs at both membrane domains. The canalicular ATP-binding cassette transporters include the bile salt export pump BSEP, which exports bile salts, and MRP2, P-glycoprotein (P-gp), and BCRP, which transport overlapping but distinct sets of substrates. MDR3 transports phospholipids into bile; it is important for biliary phospholipid secretion, rather than being a general drug-export route. On the sinusoidal side, MRP3 and MRP4 can return selected organic anions, conjugates, and bile-acid-related compounds to blood. OSTα/OSTβ is a basolateral heteromeric transporter that can mediate bile acid efflux toward blood.

The arrows in the table describe the usual physiological role for the listed route, not a universal property of every molecule in every experimental condition. In particular, many solute carrier transporters depend on gradients or coupled ion movement, while ATP-binding cassette exporters use ATP to drive transport. A transporter’s membrane address alone does not show that a given compound is a substrate or establish its net flux in vivo.

Route Bookkeeping: A Short Justification

The need to separate these routes follows from simple compartment bookkeeping. Suppose an amount of a compound is observed entering hepatocytes from blood. That entry crosses the sinusoidal boundary, regardless of what happens afterward. If the compound later appears in bile, it must cross the canalicular boundary; if it appears in blood after entering the cell, it must cross the sinusoidal boundary outward. These are distinct membrane crossings, so one transporter location cannot be inferred from the final destination alone.

For a simple illustrative accounting, let \(M_{\mathrm{in}}\) be the amount entering cells during a defined observation period, and let \(M_{\mathrm{blood}}\), \(M_{\mathrm{bile}}\), and \(M_{\mathrm{other}}\) be the amounts recovered from blood, bile, and all other measured fates. If recovery is complete and the categories do not overlap, then:

This equality is a bookkeeping identity under the stated recovery assumptions, not a transporter kinetic model. The destination categories imply which boundary must have been crossed after entry, but they do not by themselves identify the protein responsible. Metabolism, incomplete recovery, and movement between compartments during the observation period must be considered before interpreting measured amounts as route fractions.

Using Evidence to Assign Topology

Topology assignments are strongest when the experimental design preserves membrane sidedness. In polarized systems, investigators can distinguish the blood-facing and canalicular-facing compartments, then measure where a labeled substrate appears. Localization measurements can provide complementary evidence about where a transporter protein resides. Functional perturbations, such as selective inhibition or genetic reduction, can test whether a candidate transporter contributes to movement across the relevant surface.

Each evidence type answers a different question. Localization supports a membrane-address claim; substrate-dependent movement supports a route claim; and a perturbation-associated change supports a contribution claim under the conditions tested. Combining them is more informative than treating any single observation as definitive. For example, protein detected at the canalicular surface does not by itself prove that a tested drug is transported into bile by that protein.

Diagnostics, Alternatives, and Limitations

A topology interpretation should be checked against the design and the pattern of observations. Incomplete mass recovery can make apparent route fractions misleading. Poorly differentiated or nonpolarized cells may not maintain distinct blood-facing and canalicular surfaces, so measured compartments may not represent intact liver topology. A compound may bind to cells or plastic, be metabolized, or move between compartments during collection. Inhibitors may affect multiple transporters or alter membrane integrity. These issues can make a clean-looking change in one compartment ambiguous.

The principal alternative to a topology map is to describe transport only by net appearance or disappearance from a measured compartment. That can be useful for summarizing an assay, but it collapses distinct routes. A decrease in plasma concentration, for example, does not alone distinguish hepatic uptake from metabolism or biliary removal. Conversely, a compound appearing in bile has crossed into the canalicular compartment, but that observation alone does not identify the transporter or quantify how much of total hepatic elimination it accounts for.

A practical interpretation sequence is to state the membrane crossed, name the direction relative to the hepatocyte, identify the destination compartment, and then describe the level of evidence for a candidate transporter. Keep direct observations separate from mechanism claims. For example, “canalicular recovery decreased under the perturbation” is an observation; “the candidate canalicular transporter mediated all biliary export” is a stronger claim that requires additional support.

Common Pitfall: Treating Efflux as One Destination

A common mistake is to reason that any transporter called an efflux transporter must move a compound into bile. This is incorrect because efflux means movement out of the hepatocyte, not a single destination. Sinusoidal efflux returns material to blood; canalicular efflux sends it to bile. The correction is to name both the membrane and destination whenever describing an efflux pathway.

A second related error is to infer transport direction from membrane location alone. Location defines the surface on which transport can occur, but substrate recognition and driving forces determine whether the transporter contributes to movement of a particular compound under specified conditions. A pathway diagram is therefore a structured hypothesis about possible crossings, not proof of substrate transport or a quantitative prediction of clearance.